Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.

< BACK TO ARCHIVE


2022 Jul 27


Expert Rev Clin Immunol


http://www.ncbi.nlm.nih.gov/pubmed/35892247?dopt=Abstract

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.

Authors

Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
Ribeiro Dos Santos J B, Gomes R M, Ribeiro da Silva M R
Expert Rev Clin Immunol. 2022 Jul 27.
PMID: 35892247.

Abstract

Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day.
Read This Paper